Pegylated Interferon Lambda (BMS-914143) + Ribavirin/DAAs in Chronic Hepatitis C Genotype-1
Hepatitis C
Enrolment: 165 · Results not recorded
Biologic · PASylated interferon lambda (IL-28A); half-life-extended type III interferon cytokine biologic (the interferon-lambda class has reached clinical trials as peginterferon lambda).
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Hepatitis C
Enrolment: 165 · Results not recorded
Hepatitis C, Chronic
Enrolment: 56 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Myeloablative total body irradiation causing thymic damage, and allogeneic haematopoietic stem cell transplantation after myeloablative total body irradiation causing graft-versus-host disease
Graft-versus-host disease course was comparable between IL-28Ra-deficient and wild-type mice, and PASylated IL-28A did not significantly modulate graft-versus-host disease or thymic regeneration after irradiation.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.